A novel cancer vaccine shows great promise as it heads to human trials

CANCER VACCINE

Researchers concluded that the peptide called PD1-Vaxx triggered a broader polyclonal antibody response

Once the mega-storm of COVID-19 subsides, researchers and scientists can perhaps get back to addressing some of the other diseases that are plaguing humanity — one of which is Cancer. It is still by far the biggest killer for the global population in high-income countries, and despite the best efforts, an effective treatment or virus still eludes us. You might hear about a lot of alternative therapies and treatments, but none make it to mainstream medicine.

I have written about numerous cancer treatments previously — from a breakthrough in Cancer Immunotherapy to various nanoparticles to something as simple as discovering cancer-killing ‘miyabeacin’ in the Willow tree. We keep hearing of a growing number of promising cancer treatments being tested, but none so far has reached the stage where one of them can be used in the real world. Maybe the one we are going to discuss today would be the one.

Related posts:

We all know that getting dedicated time from your development team is an increasingly rare occurrence. Partnering with iConvert is akin to injecting some precious development time directly into your…

Kebiasaan adalah perilaku yang dilakukan secara berulang-ulang tanpa melalui proses berpikir karena perilaku tersebut adalah respon terhadap sesuatu yang umumnya adalah perbuatan sehari-hari (sumber…

Grove reached Unicorn status in 2019 with a $150M USD Series D round. This is impressive considering the D2C brand only launched in the US in 2016, and how it took 75 rejections until it raised its…